Figure 6. Carboplatin treatment responses associate with COSMIC signature 3 and integrated assessment of HRR deficiency classification in patient-derived xenograft models.

(A–C) LuCaP PDX TVs measured over time in mice treated with carboplatin 30 mg/kg or vehicle control IP weekly. At a TV of approximately 150 mm³ mice were randomized to treatments. Carboplatin significantly reduced the growth of iHRD(+) lines compared with vehicle with end-of-study LuCaP167 volumes of 42 ± 6 vs. 615 ± 288 (P < 0.01) and LuCaP70 end-of-study volumes of 857± 206 vs. 38 ± 7 (P < 0.01). Carboplatin did not affect the growth of iHRD(–) LuCaP 170.2 compared to vehicle treatment (P = 0.11). In all plots, each time point is represented as mean tumor volume ± SD. Tumor growth curve comparisons were determined by permutation tests.